



MedAdvisor Limited  
ACN 145 327 617  
Level 2, 971 Burke Road  
Camberwell Vic 3124  
[mymedadvisor.com/investors](http://mymedadvisor.com/investors)

**ASX RELEASE (ASX: MDR)**

## **MedAdvisor successfully completes Institutional Entitlement Offer**

- **MedAdvisor successfully completes the institutional component of its accelerated non-renounceable entitlement offer, raising approximately \$10 million**
- **MedAdvisor to complete acquisition of GuildLink Pty Ltd today**
- **Retail Entitlement Offer now fully underwritten and will raise a further \$4.6 million**

**Melbourne, Australia, 27 July, 2022** – MedTech company, MedAdvisor Limited (**MedAdvisor** or the **Company**) is pleased to announce it has successfully completed the institutional component of its accelerated non-renounceable entitlement offer (**Institutional Entitlement Offer**) announced on 25 July 2022, raising approximately \$10 million gross proceeds.

The Institutional Entitlement Offer was strongly supported by eligible institutional shareholders, who took up approximately 72.5% of their entitlements. The institutional shortfall, comprising renounced entitlements and entitlements attributable to ineligible shareholders, attracted strong demand from both existing MedAdvisor shareholders and other institutional investors.

MedAdvisor will also complete the acquisition of GuildLink Pty Ltd (**GuildLink**) today.

The retail component of the entitlement offer (**Retail Entitlement Offer**) will open on 1 August 2022. Further to the announcement on 25 July 2022, MA Moelis Australia Advisory Pty Ltd (**Moelis**) and Peloton Capital Pty Ltd (**Peloton**) have agreed to fully underwrite the Retail Entitlement Offer, which will raise approximately \$4.6 million.

Guild Group Holdings Limited participated in the Institutional Entitlement Offer, subscribing for \$4.9 million (above its full entitlement) and will be the Company's largest shareholder, holding approximately 17% of the shares on issue on completion of the Retail Entitlement Offer.

Shares issued under the Institutional Entitlement Offer will be issued and allotted on 3 August

2022.

**Commenting on the capital raise and the acquisition of GuildLink, MedAdvisor Chair Linda Jenkinson said:**

“We are pleased by the strong support shown by both existing and new institutional investors for the Institutional Entitlement Offer and the acquisition of GuildLink. I would also like to welcome the Guild Group as MedAdvisor’s largest shareholder.”

New shares issued under the Institutional Entitlement Offer and the placement to the Guild Group will rank equally with existing shares. The new shares issued under the Institutional Entitlement Offer and placement are expected to be allotted on Wednesday, 3 August 2022. Trading of the new shares issued under the Institutional Entitlement Offer will commence on a normal settlement basis on the Australian Securities Exchange (ASX) on the same day.

**Commencement of the Retail Entitlement Offer**

The retail component of the Entitlement Offer, which has been fully underwritten by MA Moelis and Peloton (collectively, **Underwriters**), will raise a further \$4.6 million. The underwriting will be pursuant to the terms of the Underwriting Agreement summarised in the Investor Presentation dated 25 July 2022. The Underwriters will be entitled to receive a management fee of 3.0%, a selling fee of 2.75% and a sub-underwriting fee of 1.0% in respect of the proceeds under the Retail Entitlement Offer.

The Retail Entitlement Offer will open on 1 August 2022 and close at 5:00pm AEST on 15 August 2022.

Eligible shareholders (being those shareholders in Australia and New Zealand) may participate in the Retail Entitlement Offer at the same price (\$0.14 per share) and offer ratio (1 new share for every 4.2 shares held) as the Institutional Entitlement Offer. Eligible shareholders will be determined according to their ownership of shares on the record date for the Retail Entitlement Offer (7.00pm AEST on 27 July 2022).

Further details in relation to the Retail Entitlement Offer will be provided in the retail offer booklet, to be despatched to eligible shareholders on 1 August 2022.

Shareholders with a registered address outside Australia and New Zealand on the Record Date will be ineligible to participate in the Retail Entitlement Offer.

MedAdvisor expects its trading halt to be lifted and MedAdvisor shares to recommence trading

on ASX from market open today.

### **Offer timetable**

An indicative timetable of the key dates in respect of the Entitlement Offer set out below:

Record Date for participation in ANREO (7.00pm AEST)	Wednesday, 27 July 2022
Retail Entitlement Offer opens and despatch of Retail Offer Booklet	Monday, 1 August 2022
Settlement of Institutional Entitlement Offer	Tuesday, 2 August 2022
Allotment of Institutional Entitlement Offer shares	Wednesday, 3 August 2022
Retail Entitlement Offer closes	Monday, 15 August 2022
Announcement of results of Retail Entitlement Offer and shortfall	Thursday, 18 August 2022
Settlement of Retail Entitlement Offer	Friday, 19 August 2022
Allotment of Retail Entitlement Offer shares	Monday, 22 August 2022
Normal trading resumes on all shares	Tuesday, 23 August 2022

**Note:** the timetable above is indicative only and may be subject to change. MedAdvisor reserves the right to amend any or all of these dates and times without notice, subject to the *Corporations Act 2001* (Cth) and the ASX Listing Rules and other applicable laws. In particular, MedAdvisor reserves the right to extend the closing date of the Retail Entitlement Offer, to accept late applications under the Retail Entitlement Offer (either generally or in particular cases) and to withdraw the ANREO without prior notice. Any extension of the closing date will have a consequential effect on the issue date of New Shares.

- ENDS -

*This document has been authorised for release by the Company Secretary.*

**For more information:**

**Company**

Annabelle Grant

Acting CFO

[corporate@medadvisor.com.au](mailto:corporate@medadvisor.com.au)

+61 3 9095 3036

**Investors**

Ronn Bechler

[ronn.bechler@marketeye.com.au](mailto:ronn.bechler@marketeye.com.au)

+61 400 009 774

**Media**

Tristan Everett

[tristan.everett@marketeye.com.au](mailto:tristan.everett@marketeye.com.au)

+61 403 789 096

**About MedAdvisor**

*MedAdvisor is a world-class medication management platform that empowers patients to more simply manage their medication and improve adherence. MedAdvisor's highly automated and intuitive software system connects patients to tools and education materials from their preferred pharmacy. MedAdvisor works with 25,000 pharmacies in the US to deliver programs to help patients take their medication safely and effectively. In Australia, MedAdvisor has connected over 2.9 million patients through more than 70% of Australian pharmacies. MedAdvisor has partnered with Cotiviti in the US, and is on track to become one of the largest players in the global digital adherence market. In 2018 and 2020, MedAdvisor was recognised in the AFR Fast 100. Visit: [mymedadvisor.com/investors](http://mymedadvisor.com/investors)*